AI in the Womb: A New Tech Wave Aims to Revolutionize Fetal Care

NEW YORK, NY – April 14, 2026 – A breakthrough technology born at Yale University is poised to overhaul fetal medicine, potentially ending the decades-long reliance on an often-unreliable monitoring method. Wavelet Medical, a startup armed with $7 million in seed funding and a strategic partnership with venture studio Aegis Ventures, is commercializing the first non-invasive, AI-powered platform to directly monitor a baby’s brain activity in the womb.

The mission is to tackle two of the most persistent problems in modern obstetrics: preventable brain injuries at birth and the soaring rate of unnecessary caesarean sections. By providing a real-time window into fetal neurological health, Wavelet aims to replace ambiguity with precision, promising a safer start to life for millions of babies and a less intervention-heavy experience for mothers.

A Decades-Old Problem in the Delivery Room

For over half a century, the standard for monitoring fetal well-being during labor has been fetal heart rate monitoring (FHM). The familiar belts strapped around an expectant mother's abdomen track the baby's heart rate, looking for patterns that might suggest distress. Yet, despite its ubiquity, the technology is notoriously imprecise.

Clinical data shows that FHM readings are indeterminate in up to 85% of births, leaving doctors to interpret ambiguous signals. This uncertainty creates a high-stakes dilemma. A misinterpretation can lead to a failure to intervene when a baby is suffering from hypoxia (a lack of oxygen), which can cause devastating and lifelong brain injuries. In the U.S. alone, more than 35,000 infants suffer such injuries at birth each year.

Conversely, the fear of missing a true distress signal drives a high rate of false positives, leading to a cascade of medical interventions, most notably emergency C-sections. While life-saving when necessary, nearly one-third of all births in the U.S. are now via caesarean, a figure the World Health Organization suggests is inflated by procedures that are not medically required. This contributes to increased risks for mothers, longer recovery times, and higher healthcare costs. The core issue remains: heart rate is an indirect, downstream indicator of distress, not a direct measurement of the organ most at risk—the brain.

The Sound of Brainwaves: How the New Technology Works

Wavelet Medical proposes a paradigm shift by listening directly to the source. The company's platform uses a series of non-invasive sensors placed on the mother's abdomen to capture faint electroencephalography (EEG) signals—the electrical activity of the fetal brain. For years, this was considered technically unfeasible due to the overwhelming "noise" from the mother's own body and surrounding environment.

The key that unlocks this data is artificial intelligence. "Until recently, noninvasive fetal EEG from the maternal abdomen was not feasible; we are now harnessing AI to reconstruct fetal EEG and translate it into quantitative markers of fetal distress," said Dr. Jose Cortes-Briones, Wavelet's Head of Science and the Yale researcher who engineered the proprietary algorithms.

These AI algorithms filter out the noise and reconstruct a clear picture of the baby's brain activity. The system specifically looks for auditory-evoked responses—subtle brainwave patterns that indicate how the baby’s brain is functioning. The presence or absence of these responses can signal neurological distress in real time, giving clinicians a clear, actionable biomarker to guide their decisions. This moves monitoring from a game of interpretation to an act of direct measurement, all without invasive scalp electrodes or added risk to the mother or baby.

The Venture Studio Bet: Accelerating Science to Standard of Care

Bringing such a transformative technology from a university lab to global markets requires more than just capital; it demands an ecosystem. This is where Aegis Ventures, a New York-based venture studio, enters the picture. With a $7 million seed investment, Aegis is not just a funder but a co-creator, deeply involved in strategy, product development, and commercialization.

This partnership is emblematic of Aegis's model, which focuses on building healthtech companies from the ground up in collaboration with scientists and health systems. The firm identified maternal-fetal medicine as an area ripe for AI-driven innovation and connected with the Wavelet team through its relationship with Yale Ventures.

"Our companies are leading the way in building proactive care solutions. The future of healthcare is anticipatory," said Murray Brozinsky, a Partner at Aegis and the Executive Chair of Wavelet's Board. "Wavelet uses AI to create a new biomarker - direct measurement of fetal brain activity. There are few missions more important than making birth safer."

For Wavelet, the partnership is an accelerator. "This is the moment breakthrough science becomes scalable impact," said Liz Golden, Wavelet's CEO. "Aegis brings the ecosystem, experience, and capital needed to accelerate product development, clinical adoption, and commercialization. Together, we have a real opportunity to redefine what 'standard of care' means in fetal medicine."

From Lab to Bedside: The Path to a New Standard

The promise of non-invasive fetal EEG is already generating significant enthusiasm among clinical leaders who have long sought better tools. The technology is currently being tested in trials involving approximately 300 patients across three sites: Yale University, LA General/USC, and the Yonsei University Health System in South Korea.

"We are encouraged by results showing that fetal brain signals can be captured non-invasively and accurately, thus offering exciting promise as a new approach, which if successful, could transform the way we deliver babies," stated Dr. David Miller, a leading Maternal-Fetal Medicine specialist and Director of the CHLA-USC Institute for Maternal-Fetal Health.

Experts believe that if the technology's predictive value is proven in expanded trials, it could rapidly become indispensable. "Wavelet captures EEG signals from the organ that first shows signs of fetal distress - the brain," noted Dr. Brian Kalish, a Neonatologist at Boston Children's Hospital and Associate Professor of Pediatrics at Harvard Medical School. "If non-invasive EEG demonstrates strong predictive value, it has a very high likelihood of becoming standard of care."

The potential impact is global. "EEG will become as universal as fetal heart rate monitoring," predicted Dr. Ja-Young Kwon, Director of the Smart Healthcare Center at Yonsei University Institute for Digital Health in South Korea. "Across Asia, mothers are deeply concerned about neurodevelopmental delay. They will demand this technology."

For Wavelet and Aegis, the next steps involve navigating expanded clinical trials and a rigorous regulatory approval process. But the goal is clear. "This isn't about building a device," Golden affirmed. "It's about building a new category in maternal health - one grounded in data, precision, and prevention. And that means more babies starting life with the healthiest brain possible."